Related Experiment Video
Updated: Feb 23, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.2K
Adaptive deep brain stimulation in Parkinson's disease.
Martijn G J de Neeling1, Bart J Keulen1, Mariëlle J Stam1
1Department of Neurology, and Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, Netherlands.
Lancet (London, England)
|February 21, 2026
Summary
Adaptive deep brain stimulation (aDBS) offers real-time, biomarker-guided treatment for Parkinson's disease. This approach promises more personalized and responsive neuromodulation compared to traditional methods.
Area of Science:
- Neurology
- Biomedical Engineering
Background:
- Parkinson's disease treatment traditionally relies on fixed deep brain stimulation (DBS).
- Adaptive DBS (aDBS) introduces real-time modulation of stimulation based on physiological markers.
Purpose of the Study:
- To outline the pathophysiological rationale for aDBS in Parkinson's disease.
- To review clinical evidence comparing aDBS with conventional DBS.
- To explore the clinical implementation and future directions of aDBS.
Main Methods:
- Review of clinical evidence comparing aDBS and conventional DBS.
- Analysis of technical developments in sensing-enabled devices and stimulation algorithms.
- Discussion of physiomarker variability, signal artifacts, and programming protocols.
Main Results:
- aDBS modulates stimulation amplitude based on subthalamic beta activity (13-30 Hz) and related physiomarkers.
- Evidence suggests potential benefits in motor improvement, side-effect reduction, and energy efficiency for aDBS.
- Limitations include physiomarker variability and lack of standardized protocols.
Conclusions:
- aDBS represents a shift towards physiomarker-guided neuromodulation for Parkinson's disease.
- Implementation requires new infrastructure, clinician training, and further real-world studies.
- aDBS holds promise for more personalized and responsive Parkinson's treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K